Erasca Inc (ERAS) Stock Price, Quote & News

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERA...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 465 6511

Website: www.erasca.com

Address:

3115 Merryfield Row, Suite 300, San Diego, United States

vu_jade Jun. 24 at 7:18 PM

$ERAS back in buy zone

0 · Reply

Chad_Thunderstock Jun. 23 at 9:46 PM

$ERAS told you all. The buying begins...

1 · Reply

pingouin01 Jun. 20 at 12:56 PM

$ERAS ,,Go have a look at Ciso stock huge reward conming soon..

0 · Reply

makedatbread88 Jun. 18 at 5:52 PM

$CDIO $ALLR $ERAS Watching these

0 · Reply

Chad_Thunderstock Jun. 18 at 2:17 PM

$ERAS this keeps dumping at open and being bought. I'm bullish. Let's head to 2+

0 · Reply

BiopharmaWatch_com Jun. 16 at 6:14 PM

🚀 Hot IND Filings Ahead! 🚀 Watch these biotech plays gearing up for IND filings in H1 & Mid-2025: • $GTBP GTB-5550 (solid tumors) – PoA 10% • $ALXO ALX2004 (EGFR ADC) – PoA 25% • $ERAS ERAS-0015 (NRAS melanoma) – PoA 12% • $MOLN MP0712 (DLL3 target) – PoA 12% • $SLDB SGT-501 (gene therapy for CPVT) – PoA 30% Early-stage catalysts worth tracking for potential moves! Get full details & real-time updates at biopharmawatch.com #Biotech #INDFilings #Catalysts #BiotechInvesting

0 · Reply

makedatbread88 Jun. 15 at 5:02 PM

Oversold biotech ideas $SCNX $IOVA $ERAS

0 · Reply

JrNannies Jun. 12 at 12:46 PM

$ERAS this stovknis dead no pulse no volume no chit chat nada

1 · Reply

Chad_Thunderstock Jun. 11 at 2:55 PM

$ERAS I'm noticing a pattern of accumulation and stop loss hits. Every opening it dumps and then bought throughout the day. So manipulation is going on IMO before the next leg up.

1 · Reply

vu_jade Jun. 10 at 8:05 PM

$ERAS locked in some nice gains… there’s a buyer here

0 · Reply

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

May 7, 2025, 8:00 AM EDT - 6 weeks ago

Erasca to Present at the Bank of America Securities Health Care Conference

Apr 29, 2025, 4:05 PM EDT - 2 months ago

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Apr 25, 2025, 11:33 AM EDT - 2 months ago

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

May 16, 2024, 8:02 PM EDT - 1 year ago

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Nov 28, 2023, 8:00 AM EST - 1 year ago

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

Aug 28, 2023, 6:05 AM EDT - 1 year ago

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Jun 5, 2023, 4:01 PM EDT - 2 years ago

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Apr 18, 2023, 9:00 AM EDT - 2 years ago

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development

Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates

Mar 23, 2023, 4:01 PM EDT - 2 years ago

0 · Reply

Chad_Thunderstock Jun. 23 at 9:46 PM

$ERAS told you all. The buying begins...

1 · Reply

pingouin01 Jun. 20 at 12:56 PM

$ERAS ,,Go have a look at Ciso stock huge reward conming soon..

0 · Reply

makedatbread88 Jun. 18 at 5:52 PM

$CDIO $ALLR $ERAS Watching these

0 · Reply

Chad_Thunderstock Jun. 18 at 2:17 PM

$ERAS this keeps dumping at open and being bought. I'm bullish. Let's head to 2+

0 · Reply

BiopharmaWatch_com Jun. 16 at 6:14 PM

0 · Reply

makedatbread88 Jun. 15 at 5:02 PM

Oversold biotech ideas $SCNX $IOVA $ERAS

0 · Reply

JrNannies Jun. 12 at 12:46 PM

$ERAS this stovknis dead no pulse no volume no chit chat nada

1 · Reply

Chad_Thunderstock Jun. 11 at 2:55 PM

$ERAS I'm noticing a pattern of accumulation and stop loss hits. Every opening it dumps and then bought throughout the day. So manipulation is going on IMO before the next leg up.

1 · Reply

vu_jade Jun. 10 at 8:05 PM

$ERAS locked in some nice gains… there’s a buyer here

0 · Reply

vu_jade Jun. 6 at 6:22 PM

$ERAS still a buyer here

0 · Reply

Chad_Thunderstock Jun. 6 at 3:35 PM

$ERAS entered. Looking st target of 2.40-2.70 exit.

0 · Reply

vu_jade Jun. 6 at 3:35 PM

$ERAS headed to “deuce”

0 · Reply

Chad_Thunderstock Jun. 6 at 3:17 PM

$ERAS

0 · Reply

vu_jade Jun. 6 at 2:52 PM

$ERAS great spot

0 · Reply

vu_jade Jun. 6 at 12:56 PM

$ERAS going to $2+

0 · Reply

vu_jade Jun. 6 at 11:30 AM

$ERAS buy the dip, before the next rip.

0 · Reply

vu_jade Jun. 5 at 7:03 PM

$ERAS only a pause before it rallies back to $2

0 · Reply

Chartwatcher1 Jun. 5 at 6:53 PM

Adding $ERAS long, 60 min chart looking good, suggesting $1.54 -$1.56, is new support level.

0 · Reply

vu_jade Jun. 5 at 5:29 PM

$ERAS there’s a buyer in here…. Next sale over $2

0 · Reply

vu_jade Jun. 5 at 5:18 PM

$ERAS buyers will be back ..

0 · Reply

vu_jade Jun. 5 at 4:52 PM

$ERAS $2.10 magnet ..

0 · Reply

Market Cap	393.77M
Revenue (ttm)	0.00
Net Income (ttm)	-161.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	586,100
Avg Vol	1,486,354
Day's Range	N/A - N/A
Shares Out	283.29M
Stochastic %K	45%
Beta	1.09
Analysts	Strong Sell
Price Target	$4.83